Cargando…
A landscape of response to drug combinations in non-small cell lung cancer
Combination of anti-cancer drugs is broadly seen as way to overcome the often-limited efficacy of single agents. The design and testing of combinations are however very challenging. Here we present a uniquely large dataset screening over 5000 targeted agent combinations across 81 non-small cell lung...
Autores principales: | Nair, Nishanth Ulhas, Greninger, Patricia, Zhang, Xiaohu, Friedman, Adam A., Amzallag, Arnaud, Cortez, Eliane, Sahu, Avinash Das, Lee, Joo Sang, Dastur, Anahita, Egan, Regina K., Murchie, Ellen, Ceribelli, Michele, Crowther, Giovanna S., Beck, Erin, McClanaghan, Joseph, Klump-Thomas, Carleen, Boisvert, Jessica L., Damon, Leah J., Wilson, Kelli M., Ho, Jeffrey, Tam, Angela, McKnight, Crystal, Michael, Sam, Itkin, Zina, Garnett, Mathew J., Engelman, Jeffrey A., Haber, Daniel A., Thomas, Craig J., Ruppin, Eytan, Benes, Cyril H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307832/ https://www.ncbi.nlm.nih.gov/pubmed/37380628 http://dx.doi.org/10.1038/s41467-023-39528-9 |
Ejemplares similares
-
Potent and selective effect of the mir-10b inhibitor MN-anti-mir10b in human cancer cells of diverse primary disease origin
por: Yoo, Byunghee, et al.
Publicado: (2018) -
Synthetic lethality across normal tissues is strongly associated with cancer risk, onset, and tumor suppressor specificity
por: Cheng, Kuoyuan, et al.
Publicado: (2021) -
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition
por: Cai, Jinyang, et al.
Publicado: (2022) -
mTOR inhibition overcomes RSK3-mediated resistance to BET inhibitors in small cell lung cancer
por: Kumari, Anju, et al.
Publicado: (2023) -
Genome‐wide prediction of synthetic rescue mediators of resistance to targeted and immunotherapy
por: Sahu, Avinash Das, et al.
Publicado: (2019)